bronchial asthma
Conditions
Interventions
asthma patients:no intervention
Wild type of GLCCI1:treatment with Flixotide
Heterozygous of GLCCI1:treatment with Flixotide
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. mild to moderate persistent asthma that meet the 2008 diagnostic criteria established by Chinese Medical Association Respiratory Diseases Asthma Study Group; 2. Age 18-70 years old , male or female; 3. Bronchial provocation test or Bronchodilation test positive; 4. No use of systemic or inhaled corticosteroids during the last 4 weeks; 5. No use of leukotriene receptor modulators, theophylline derivatives andmast cell stabilizers Within 2 weeks before the test; 6. No use of long-acting ß2 agonists, oral ß2 agonists or inhaled anti- cholinergic receptor 1 week before the test; 7.Abscent of without respiratory infections andsystemic infections, particularly acute respiratory infections , tuberculosis, fungal infections 4 weeks before the test; 8. Abscent of acute asthma exacerbations andhospitalizations 4 weeks before the test; 9. Did not receive any study medication 4 weeks before the test; 10. No inhaled corticosteroids, ß2 agonists allergies; 11. No serious heart, liver, kidney andother systemic disorders; 12. Agreed to join the study andsigned a written informed consent
Exclusion criteria
Exclusion criteria: 1. Intermittent status asthma, severe asthma andacute exacerbation of asthma; 2. Occupational asthma or aspirin or non- steroidal anti-inflammatory drugs -related asthma; 3. Life-threatening acute asthma exacerbations occurred within one year before the test; 4. Using of monoclonal anti-IgE Within 6 months prior to the test; 5. Recent drug use that can lead to bronchospasm or affect the Forced lung function; 6. Allergic to inhaled corticosteroids, ß2 agonists allergy, antibiotics or a history of food or drug -related serious allergic reactions; 7. Have serious disease of heart, liver, kidneys, lungs, gastrointestinal tract, endocrine andblood system diseases. Treated or untreated malignancies of any organ; 8. Obvious potential medical conditions( such as infection, blood diseases, kidney disease, liver disease, coronary heart disease or other cardiovascular diseases , cerebrovascular diseases, endocrine or gastrointestinal disease. ) that may affect the interpretation of the results 1 year before the test. 9. Other history of active lung diseases except asthma such as chronic bronchitis , chronic obstructive pulmonary disease, allergic granulomatous vasculitis, allergic bronchopulmonary aspergillosis; 10. Before the test, an average annual smoking. Former smokers should quit smoking in the 12 months prior to trial; 11. History of alcoholism anddrug abuse; 12. Pregnant andlactating women; 13. With psychiatric disorders; 14. had a hospitalization due to asthma exacerbations or failed to complete the whole process of determination during the study; 15. Not expected to complete the study or unable to continue to participate in planned visits; 16. Unable or unwilling to comply with research operations or study visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| genotype of GLCCI1;expression level of GLCCI1;forced pulmonary function test;blood routine examination; | — |
Secondary
| Measure | Time frame |
|---|---|
| ACT score;AQLQ score;NGF expression;expression level of Epinephrine;expression level of Norepinephrin; | — |
Countries
China
Contacts
Public ContactJuntao Feng
Xiangya Hospital, Central South University
Outcome results
None listed